• Pipeline
  • ASO

ASO (Anti-sense Oligonucleotide)

Overview

01

Next Generation ASO

  • Improved ASO with enhanced dosing convenience and safety

02

Science & Innovation Features

  • Next generation ASO with improved safety and efficacy
  • Improved dosing convenience through IV/SC * administration compared to the 1st generation that requires infusion

    * IV: Intravenous Injection / SC: Subcutaneous Injection

  • Minimize potential toxicity issues by changing the administration route and increasing efficacy with modification

Non-clinical
Study

Synergistic anti-cancer effect of tumor growth inhibition with pembrolizumab has been confirmed in humanized mouse model.

Melanoma (A2058) Mouse Model

Pancreatic Cancer (AsPC-1) Mouse Model